BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $38
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $32 to $38.
BTIG analyst Julian Harrison maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and raises the price target from $32 to $38.